Irritable Colon Clinical Trial
Official title:
A Double-blind, Randomised, Placebo Controlled, Single Dose, Two-period Crossover Study to Investigate the Therapeutic Potential of the TRPV1 Antagonist SB-705498 in Treatment of Subjects With Rectal Hypersensitivity Including Irritable Bowel Syndrome.
SB-705498 has demonstrated efficacy in several preclinical and human experimental pain models. This study will investigate the efficacy of SB-705498 in patients with rectal pain. This will be a double-blind, placebo-controlled, two-way crossover study. 21 patients with faecal urgency (Group 1), and 21 patients with IBS (Group 2) will complete this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01855711 -
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
|
Phase 2 | |
| Terminated |
NCT00423345 -
Colon Investigation - Factors Determining Choice of Procedure
|
||
| Completed |
NCT00101985 -
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
|
Phase 2 | |
| Completed |
NCT00376896 -
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00067561 -
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
|
Phase 3 | |
| Completed |
NCT00067457 -
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
|
Phase 3 | |
| Completed |
NCT00385099 -
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
|
Phase 2 | |
| Completed |
NCT00370032 -
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
|
Phase 4 |